BACKGROUND: Historically, the 5-year overall survival (OS) for @entity3 ( @entity3 ) was less than 40%. The strategy of post-operative induction chemotherapy (IC) followed by hyperfractionated accelerated radiotherapy (HART) and response directed high dose chemotherapy (HDC) was reported in a single center study to improve 5-year OS to 73%. We report outcomes of this strategy in UK. METHODS: Questionnaires were sent to all 20 UK pediatric oncology primary treatment centers to collect retrospective data on delivered treatment, @entity137 and survival with this strategy in @entity1 aged 3-19 years with @entity3 . RESULTS: Between February 2009 and October 2011, 34 @entity1 fulfilled the entry criteria of the original study. The median age was 7 years (range 3-15). Median interval from surgery to HART was 109 versus 85 days in the original series. The incidence of grade 3 or 4 @entity1503 with IC and HDC was 83-100%. All 16 @entity1 who achieved complete response by the end of the regimen remain in remission but only three of 18 @entity1 with lesser responses are still alive (P   <   0.0001). With a median follow-up of 45 months for survivors, the estimated 3-year OS is 56% (95% CI 38, 71). This result is outside the 95% CI of the original study results and encompasses the historical survival result of 40%. CONCLUSION: Within the limits of statistical significance, we did not replicate the improved survival results reported in the original series. The reasons include differences in @entity1 sub-groups and protocol administration. International randomized phase III studies are needed. Pediatr @entity5 2015;9999:1-8    2015 Wiley Periodicals, Inc.

The UK Experience of a Treatment Strategy for Pediatric XXXX Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy).

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Blood Cancer'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological toxicities'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic medulloblastoma', 'MMB']
@entity3 :: (MESH:D009362,Disease) :: ['Metastatic Medulloblastoma']
